Joash Lazarus, MD
Neurology · Atlanta, GANPI 1720374754
Payments from drug & device makers
Across 1,574 payments — averaging $864.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- TG Therapeutics, Inc.$221K
- Neurocrine Biosciences, Inc.$180K
- EMD Serono, Inc.$177K
- Biogen$111K
- AbbVie$106K
- MDD US Operations, LLC$88K
- plus $478K from 52 others
Across 2 payments — averaging $3500.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Acadia Pharmaceuticals Inc$7K
What the payments were for
- Consulting fees$111,00510%
- Speaking & faculty fees$897,29082%
- Travel & lodging$45,7444%
- Food & beverage$36,0143%
- Education$1,6940%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,361,338 in reported general payments places this provider in the 95th percentile of 506 neurology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ApokynApomorphine Hcl | 17 | $392,301 |
| Kesimpta PenOfatumumab | 45 | $392,281 |
| GocovriAmantadine Hcl | 95 | $271,945 |
| Avonex (4 Pack)Interferon Beta-1a | 19 | $157,311 |
| TysabriNatalizumab | 17 | $138,194 |
| Austedo XrDeutetrabenazine | 16 | $101,278 |
| GlatopaGlatiramer Acetate | 19 | $80,238 |
| NuplazidPimavanserin Tartrate | 12 | $55,471 |
| RytaryCarbidopa/Levodopa | 41 | $49,970 |
| Teriflunomide | 61 | $46,533 |
| InbrijaLevodopa | 17 | $41,556 |
| NeuproRotigotine | 36 | $31,688 |
| Nurtec OdtRimegepant Sulfate | 19 | $20,776 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 438 | $17,353 |
| Aimovig AutoinjectorErenumab-Aooe | 20 | $14,415 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| BiogenAvonex (4 Pack), Tysabri | $110,700 | $295,50536 claims |
| MDD US Operations, LLCGocovri | $88,292 | $271,94595 claims |
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $79,768 | $101,27816 claims |
| Acadia Pharmaceuticals IncNuplazid | $54,409 | $55,47112 claims |
| Amneal Pharmaceuticals LLCRytary | $4,383 | $49,97041 claims |
| Acorda Therapeutics, IncInbrija | $58,979 | $41,55617 claims |
| UCB, Inc.Neupro | $368 | $31,68836 claims |
| PfizerNurtec Odt | $151 | $20,77619 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 506 neurology providers in Georgia.
Other neurology in Atlanta
- James LahAtlanta$6.8M
- Jonathan GlassAtlanta$5.1M
- Allan LeveyAtlanta$4.2M
- Ben ThrowerAtlanta$3.7M
- Jeffrey EnglishAtlanta$3.1M
- Dennis LaceyAtlanta$2.8M
- Julio FlaminiAtlanta$1.6M
- Frank BerensonAtlanta$1.2M
- Stewart FactorAtlanta$1M
- Matthews GwynnAtlanta$775K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.